Subhadip Pati

Employment

• University of North Carolina at Chapel Hill Postdoctoral Research Associate
  2023 - Present

Education

• Bose Institute PhD
  2017 - 2023
• Bose Institute Integrated MSc-Phd
  2015 - 2017

Projects & Funding

Projects & funding information is unavailable.

Publications (20)

• Supplementary Tables from Tumor-Associated CD19+CD39− B Regulatory Cells Deregulate Class-Switch Recombination to Suppress Antibody Responses
  2025 DOI: 10.1158/2326-6066.30720873
  +Save
• The Role of Nuclear Factor-κB in Cancer Immunity and Immunoediting
  Cancer Control 2025 DOI: 10.1177/10732748251406677
  +Save
• hsa-miR-5688 inhibits FOXC1-OCT4/SOX2 feedforward loop that drives chemoresistance in breast cancer stem cells
  Molecular Therapy Oncology 2025 DOI: 10.1016/j.omton.2025.200982
  +Save
• <scp>FOXP3</scp> Transcriptionally Activates Fatty Acid Scavenger Receptor <scp>CD36</scp> in Tumour‐Induced Treg Cells
  Immunology 2025 DOI: 10.1111/imm.13887
  +Save
• Breast cancer stem cells convert anti-tumor CD4+ T cells to pro-tumor T regulatory cells: Potential role of exosomal FOXP3
  Cellular Immunology 2025 DOI: 10.1016/j.cellimm.2025.104931
  +Save
• Supplementary Figures from Tumor-Associated CD19+CD39− B Regulatory Cells Deregulate Class-Switch Recombination to Suppress Antibody Responses
  2025 DOI: 10.1158/2326-6066.30720876
  +Save
• Nuclear factor kappa-B: The El Dorado of inflammatory immune response
  Journal of Cellular and Molecular Immunology 2024 DOI: 10.46439/immunol.3.025
  +Save
• Supplementary Figures from Tumor-Associated CD19+CD39− B Regulatory Cells Deregulate Class-Switch Recombination to Suppress Antibody Responses
  2023 DOI: 10.1158/2326-6066.22546568
  +Save
• Tumor-Associated CD19+CD39− B Regulatory Cells Deregulate Class-Switch Recombination to Suppress Antibody Responses
  Cancer Immunology Research 2023 DOI: 10.1158/2326-6066.CIR-21-1073
  +Save
• Supplementary Tables from Tumor-Associated CD19+CD39− B Regulatory Cells Deregulate Class-Switch Recombination to Suppress Antibody Responses
  2023 DOI: 10.1158/2326-6066.22546565
  +Save